01/17/23 8:45 AMAMEX : AIM clinical trialAIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical CenterAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), anRHEA-AIvery positive
01/09/23 8:05 AMAMEX : AIM covid-19AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or PreventionAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, theRHEA-AIneutral
01/05/23 8:45 AMAMEX : AIM conferencesAIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,RHEA-AIneutral
12/12/22 9:00 AMAMEX : AIM managementAIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific OfficerAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research andRHEA-AIvery positive
12/08/22 8:05 AMAMEX : AIM AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy SubjectsIntranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British Society for Immunology Congress 2022RHEA-AIneutral
12/02/22 10:45 AMAMEX : AIM AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, theRHEA-AIneutral
11/15/22 7:00 AMAMEX : AIM earningsAIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” orRHEA-AIneutral
11/14/22 7:00 AMAMEX : AIM AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable toRHEA-AIneutral
11/09/22 9:00 AMAMEX : AIM AIM ImmunoTech Announces Corporate Governance EnhancementsAIM ImmunoTech Inc. today announced the following corporate governance enhancements:. Mitchell continued:“ Over the past year AIM ImmunoTech has made significant progress achieving multiple clinical and regulatory advances. Clinical milestones include the publication in Cancers of an early access program sponsored by the Dutch government which...RHEA-AIvery positive
11/03/22 12:34 PMAMEX : AIM AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual MeetingAIM ImmunoTech Inc. today announced that shareholders have re-elected all three of the Company’ s directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Company’ s Annual Meeting of Shareholders held today. The Company will file the final voting results on a Form 8- K with the Securities and Exchange Commission. AIM ImmunoTech Inc. is an...RHEA-AIneutral